Browse the evidence

Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.

GLP-1 drugs might reduce the 'high' or addictive feeling associated with nicotine, which could make it easier for smokers to quit or use nicotine-based therapies without the usual addiction risks.

Inhibition of the p38 MAPK pathway in white adipose tissue promotes the reprogramming of white adipocytes to beige adipocytes, leading to resistance against diet-induced obesity.

Research suggests that targeting specific signaling pathways like p38 MAPK could potentially help convert energy-storing white fat into energy-burning beige fat, offering a potential future therapeutic strategy for obesity.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe food aversion, dehydration, and acute kidney injury when used without intensive clinical monitoring.

If you are taking GLP-1 agonists (like Ozempic or Mounjaro), do not use them without regular medical supervision. Watch for signs of extreme food aversion, dehydration, or rapid weight loss. If you experience severe side effects like kidney issues or inability to eat, contact your doctor immediately. These drugs are powerful and require monitoring, especially if you have a history of eating disorders or have had bariatric surgery.

Environmental cold exposure and specific bioactive compounds (e.g., resveratrol, menthol) induce the browning of white adipose tissue (WAT) and activation of brown adipose tissue (BAT), thereby increasing energy expenditure and improving metabolic health.

You can potentially boost your metabolism by exposing yourself to cold or consuming specific compounds like resveratrol or menthol. These actions encourage your body to convert energy-storing white fat into energy-burning brown or beige fat. While cold exposure is effective, it may be uncomfortable, so exploring dietary sources of these compounds or exercise-induced browning might be more sustainable alternatives for long-term metabolic health.

Obesity and aging are associated with the 'whitening' of brown adipose tissue, characterized by lipid accumulation, loss of mitochondria, and impaired thermogenesis, which contributes to metabolic dysfunction.

As you age or gain weight, your body's ability to burn fat as heat (via brown fat) naturally declines, contributing to further weight gain and metabolic issues. This process is called 'whitening.' While you cannot reverse aging, you can potentially slow this decline by maintaining physical activity and exposing yourself to cold, which may help preserve your brown fat function and metabolic health.

Aging blunts the ability for serial sarcomerogenesis (addition of new sarcomeres in series), leading to shortened fascicle length and impaired muscle mechanical function, primarily due to age-related impairments in mechanotransduction pathways like mTOR, IGF-1, and SRF signaling.

For older adults, maintaining or improving muscle function may require specific interventions that promote muscle lengthening, such as eccentric resistance training or chronic stretching. While muscle mass loss is common, the shortening of muscle fascicles (due to loss of serial sarcomeres) contributes significantly to stiffness and reduced power. Targeted training that emphasizes the lengthening phase of movements may help mitigate these age-related architectural changes, though the response may be slower or smaller than in younger individuals.

Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.

Understand that exercise is a systemic therapy. When you move, your muscles release signals that improve the health of your heart, brain, and fat tissue, not just the muscles themselves.

Tirzepatide (TRZD) may increase the risk of cancer progression, specifically pancreatic and medullary thyroid cancer (MTC), through GLP-1R/GIPR-mediated activation of oncogenic pathways (PI3K/Akt/mTOR, Ras-Raf-ERK) and calcitonin release, particularly in patients with prior pancreatitis or family history of MTC.

If you have a personal or family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), you should not use Tirzepatide. If you have a history of pancreatitis, use with caution and monitor for symptoms. For other diabetic patients, the long-term cancer risk is currently unknown, but the drug is approved for weight loss and glucose control. Discuss your specific cancer history with your provider before starting.

Tirzepatide (TRZD) and other GLP-1R/GIPR agonists may exhibit anti-cancer properties by sensitizing cancer cells to chemotherapy, inducing apoptosis, and inhibiting proliferation via pathways like PI3K/Akt/mTOR and AMPK, particularly in pancreatic, breast, and colorectal cancers.

Current research shows that drugs like Liraglutide and Exenatide can kill cancer cells or make chemo work better in lab mice. However, there is no proof yet that Tirzepatide does this in humans. Do not use these drugs as a cancer treatment outside of clinical trials.

High-dose omega-3 PUFA supplementation (1-4 g/d) increases the risk of new-onset atrial fibrillation, particularly in elderly patients or those with prior myocardial infarction, likely by prolonging action potential duration via Piezo1 channel modulation.

If you are taking high-dose omega-3 supplements (1-4 grams daily), especially if you are older or have had a heart attack, be aware that this may increase your risk of developing atrial fibrillation (an irregular heartbeat). Consult your doctor before maintaining high doses, as the benefits for inflammation may be offset by this specific cardiac risk.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) causes a significant decrease in fecal straight short-chain fatty acids (SCFAs), including acetate, propionate, butyrate, and valerate, likely due to altered dietary intake and microbiota fermentation.

If you have had bariatric surgery, expect your gut bacteria to produce fewer beneficial fatty acids (SCFAs) like butyrate. This is a normal physiological change due to the surgery and dietary shifts. To support your gut health, focus on the recommended post-surgical diet, which emphasizes protein and gradually reintroduces fiber-rich foods as tolerated, under the guidance of your healthcare team.

Peri-operative use of GLP-1 receptor agonists delays gastric emptying, increasing the risk of retained gastric contents and pulmonary aspiration during anesthesia, particularly in patients without diabetes or those recently initiating therapy.

If you take GLP-1 medications (like Ozempic or Wegovy) before surgery, tell your anesthesiologist immediately. These drugs slow stomach emptying, which can cause dangerous aspiration during anesthesia. You may need to fast longer or follow a clear-liquid diet for 24 hours before your procedure, even if it is elective. Do not assume standard fasting rules apply.

Metabolic and bariatric surgery (MBS) often results in substantial weight regain in patients with monogenic or syndromic obesity, particularly those with MC4R pathway variants, making it less effective than targeted pharmacotherapy for these groups.

If you have a known genetic form of obesity, discuss the long-term risks of bariatric surgery with your doctor. Studies show that patients with MC4R pathway variants often regain significant weight after surgery because the underlying genetic hunger drive remains unaddressed.

Dual incretin agonists (GLP-1/GIP) and triple agonists (GLP-1/GIP/Glucagon) show superior efficacy in reducing liver fat, inflammation, and fibrosis compared to GLP-1 mono-agonists in animal models, suggesting potential for enhanced clinical outcomes in MASLD.

Research suggests that newer 'dual' (GLP-1/GIP) and 'triple' (GLP-1/GIP/Glucagon) agonists may offer even greater benefits for liver health than current GLP-1 drugs, particularly in reducing liver fat and inflammation. These are still largely in clinical trials or early adoption phases for liver disease. If standard GLP-1 therapy is insufficient, discuss these newer multi-agonist options with your hepatologist or endocrinologist, keeping in mind that long-term human data for liver-specific outcomes is still being gathered.

Engineered bacteria (SYNB1020) that overproduce arginine to convert gut ammonia into L-arginine successfully lower systemic ammonia and improve survival in animal models of liver failure, but failed to show efficacy in a Phase Ib/IIa clinical trial for cirrhosis patients.

While engineered bacteria show promise in animals for clearing liver toxins, current clinical trials for liver disease patients have not yet succeeded. Do not expect this specific therapy to be available or effective for cirrhosis at this time.

Engineered bacteria producing GLP-1 or butyrate can improve glucose tolerance, insulin sensitivity, and reduce body weight in animal models of obesity and diabetes.

Research shows that engineered gut bacteria can produce hormones like GLP-1 or butyrate to improve metabolism in animals. This is a promising area for future oral treatments for diabetes and obesity, but it is not yet a standard therapy.

Activation of Gq-coupled receptors in brown and beige adipocytes generally suppresses thermogenic competence, whereas specific Gq receptors (like GPR120) can boost lipid oxidation and mitochondrial respiration.

The role of Gq receptors in fat burning is complex. While some Gq receptors (like those activated by acetate) may reduce fat-burning capacity, others (like GPR120, activated by fatty acids) can boost it. This complexity makes it a challenging target for simple drug development.

GLP-1 RAs show therapeutic potential in neurological disorders, including Alzheimer's and Parkinson's disease, by reducing amyloid-β/tau pathology, neuroinflammation, and promoting neuronal survival.

GLP-1 medications are being studied for Alzheimer's and Parkinson's disease. Some trials show promise in slowing brain volume loss, but results are mixed. They are not yet a standard treatment for these conditions. Consult a neurologist if interested in clinical trials.

None of the combined antidiabetic therapies (DPP4i, GLP1RA, TZD, SGLT2i) showed a significant change in blood pressure compared to metformin alone in women with PCOS.

Do not expect adding DPP4 inhibitors, GLP1RAs, TZDs, or SGLT2 inhibitors to metformin to significantly lower your blood pressure. Focus on these combinations for glycemic, lipid, or weight management instead.

GLP-1 receptor agonists (GLP-1RAs) are associated with an emerging signal of suicidality, including suicidal ideation, attempts, and completed suicide, based on pharmacovigilance data, though large randomized controlled trials have not demonstrated a statistically significant causal increase in risk.

GLP-1 medications (like Ozempic or Wegovy) have been linked to reports of suicidal thoughts in pharmacovigilance databases, creating a safety signal. However, large clinical trials involving thousands of patients have not found a statistically significant increase in psychiatric events compared to placebo. The absolute risk appears to be very low. Clinicians should monitor patients, especially those with a history of mental health conditions, but the proven benefits for weight loss and heart health generally outweigh this rare risk for most users.

Chronic consumption of monosodium glutamate (MSG) is associated with increased risk of obesity and weight gain, primarily through mechanisms involving hypothalamic damage, leptin resistance, and altered gut microbiota.

While MSG is legally safe, emerging research suggests high chronic intake, especially from processed foods with hidden MSG, may disrupt appetite regulation and contribute to weight gain. To mitigate potential risk, prioritize whole foods and check labels for hidden sources like hydrolyzed protein or yeast extract.

Long-acting GLP-1 receptor agonists (GLP-1RAs) attenuate obesity and reverse leptin resistance by reshaping gut microbiota to increase Akkermansia muciniphila, which produces inosine to activate the macrophage A2A pathway, thereby reducing adipocyte leptin levels.

This research suggests that GLP-1 medications (like semaglutide or liraglutide) may work partly by changing your gut bacteria to produce a molecule called inosine. This molecule helps reduce leptin, a hormone that regulates fat storage. While you cannot directly control this pathway, maintaining gut health through diet may support the effectiveness of these medications.

Specific additives found in UPFs, such as carrageenan and endocrine-disrupting chemicals like Bisphenol-A (BPA) and acrylamide, contribute to T2DM risk through mechanisms involving insulin resistance, inflammation, and gut microbiota alteration.

Be aware that certain additives (carrageenan, specific emulsifiers) and packaging-derived chemicals (BPA, phthalates) in UPFs may promote insulin resistance and inflammation. Reducing intake of products containing these specific ingredients, especially sugary beverages and processed meats, may lower T2DM risk.

Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.

If you have moderate OSA and are not sleepy (only snoring), ask your doctor if you can try tirzepatide alone. Since CPAP's benefit in asymptomatic moderate OSA is unclear, tirzepatide might resolve your OPA without the need for a machine. This requires monitoring and may not be suitable for everyone.